Notch receptor and effector expression in von Hippel-Lindau disease–associated central nervous system hemangioblastomas

Laboratory investigation

Restricted access

Object

Central nervous system hemangioblastomas are the most common manifestation of von Hippel-Lindau (VHL) disease, an autosomal dominant tumor suppressor syndrome that results in loss of VHL protein function and continuous upregulation of hypoxia-inducible factors. These tumors are composed of neoplastic stromal cells and abundant vasculature. Stromal cells express markers consistent with multipotent embryonically arrested hemangioblasts, which are precursors for hematopoietic and vascular lineages. Notch receptors are transmembrane signaling molecules that regulate multiple developmental processes including hematopoiesis and vasculogenesis. To investigate the importance of notch signaling in the development of VHL disease–associated CNS hemangioblastomas, the authors examined the presence of the four notch receptors and downstream notch effectors in this setting.

Methods

The authors used surgical specimens obtained from confirmed VHL-associated hemangioblastomas. Immunohistochemical analysis for the four notch receptors and the downstream effectors was performed on formalin-fixed paraffin-embedded sections. Western blot analysis for HES1 was performed on frozen specimens.

Results

All four notch receptors are present in hemangioblastomas. NOTCH1 and NOTCH4 receptors were widely and prominently expressed in both the stromal and vascular cells, NOTCH2 receptor expression was limited to primarily stromal cells, and NOTCH3 receptor expression was limited to vascular cells. All 4 receptors displayed a nuclear presence. Immunohistochemical analysis also demonstrated that downstream notch effectors, HES1 and HES5, were uniformly expressed in tumor stromal and vascular cells, but HES3, HEY1, and HEY2 were not. Strong HES1 expression was confirmed by Western blot analysis.

Conclusions

The presence of all four notch receptors and downstream effector molecules suggests that the notch signaling pathway plays a critical role in the maintenance of the undifferentiated pluripotent phenotype of these tumors and in the associated vascular response. Moreover, the prominent expression of notch receptors in VHL-associated CNS hemangioblastomas reveals a new and possibly potent therapeutic target.

Abbreviations used in this paper: ABC/DAB = avidin-biotin complex/3,3′-diaminobenzidine; HIF = hypoxia-inducible factor; ICD = intracellular domain; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau.

Article Information

Address correspondence to: Marsha J. Merrill, Ph.D., 10 Center Drive, MSC 1414, Building 10, Room 3D-20, Bethesda, Maryland 20892-1414. email: merrillm@ninds.nih.gov.

Please include this information when citing this paper: published online June 10, 2011; DOI: 10.3171/2011.5.JNS11271.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Immunohistochemical analysis of notch receptors 1 through 4 in a representative CNS hemangioblastoma. A: NOTCH1 immunoreactivity is distributed uniformly, with cytoplasmic and nuclear staining observed in both the stromal and vascular cells. B: NOTCH2 immunoreactivity is confined to the nucleus. C: NOTCH3 immunoreactivity is strongly expressed in the vascular component of the tumor. D: NOTCH4 immunoreactivity is similar to NOTCH1, with cytoplasmic and nuclear staining observed in both the stromal and vascular cells. E: Nonimmune rabbit IgG control. F: Hematoxylin & eosin staining demonstrates the typical hemangioblastoma appearance with “foamy” stromal cells and abundant vasculature. All antibodies were raised against the C-terminus of the molecule and do not distinguish between the full-length and the cleaved forms. Staining for all four Notch receptors was performed at the same time in the same tumor. Photomicrographs were taken from the same area of the tumor with the same exposure settings, original magnification × 40. Bar = 100 μm.

  • View in gallery

    Cellular localization of notch receptors. A: NOTCH1 antibody to the C-terminus recognizes both full-length and cleaved NOTCH1 and reacts with both cytoplasmic and nuclear Notch. B: Antibody against NOTCH ICD recognizes only the signaling portion of notch and localizes to the nucleus. The same area of the same tumor is presented in A and B. C: NOTCH2 displays a nuclear localization in stromal cells with only occasional reactivity in vascular cells. D: NOTCH3 staining from the same area presented in panel C reveals an exclusively vascular localization. E: Low-magnification image of NOTCH3 immunoreactivity displaying abundant vasculature. NOTCH3-positive vasculature of multiple morphologies, including large thick- and thin-walled vessels as well as microvessels, is observed. F: NOTCH4 reactivity is seen in the cytoplasm and nuclei of both stromal and vascular cells. Asterisks indicate stromal cells. v = blood vessel. Bar = 20 μm (A–D, and F); bar = 100 μm (E).

  • View in gallery

    Immunohistochemical staining of Notch downstream effectors in a representative CNS hemangioblastoma. A: HES1 was observed in the nuclei of both stromal cells and blood vessels. B: Western blot analysis of 4 hemangioblastomas also demonstrating the presence of HES1. C: Scattered, faint HES3 immunoreactivity observed in the nuclei of some cells. D: HES5 displaying a pattern similar to HES1 although not as intense. E: HEY1 staining is not distinguishable from the negative IgG control (not shown). F: Scattered, faint HEY2 immunoreactivity observed in the nuclei of some cells. Staining for all 5 effector molecules was performed in the same tumor. Original magnification × 40. Bar = 100 μM.

References

1

Böhling TPlate KHHaltia MJAlitalo KNeumann HPHVon Hippel-Lindau disease and capillary haemangioblastoma. Kleihues PCavenee WK: Pathology and Genetics of Tumors of the Nervous System World Health Organization classification of tumors. LyonIARC Press2000. 223226

2

Calzada MJ: Von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clin Transl Oncol 12:1601652010

3

Dikic ISchmidt MH: Notch: implications of endogenous inhibitors for therapy. Bioessays 32:4814872010

4

Fleisher ASRaman RSiemers ERBecerra LClark CMDean RA: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:103110382008

5

Gläsker SLi JXia JBOkamoto HZeng WLonser RR: Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res 66:416741722006

6

Gustafsson MVZheng XPereira TGradin KJin SLundkvist J: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9:6176282005

7

Harper JAYuan JSTan JBVisan IGuidos CJ: Notch signaling in development and disease. Clin Genet 64:4614722003

8

Hofmann JJIruela-Arispe ML: Notch signaling in blood vessels: who is talking to whom about what?. Circ Res 100:155615682007

9

Karsan A: The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol 83:14232005

10

Katoh MKatoh M: Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 31:4614662007

11

Konishi JKawaguchi KSVo HHaruki NGonzalez ACarbone DP: Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67:805180572007

12

Li JLHarris AL: Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 14:309431102009

13

Liu HZhang WKennard SCaldwell RBLilly B: Notch3 is critical for proper angiogenesis and mural cell investment. Circ Res 107:8608702010

14

Liu JSato CCerletti MWagers A: Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 92:3674092010

15

Lonser RRGlenn GMWalther MChew EYLibutti SKLinehan WM: von Hippel-Lindau disease. Lancet 361:205920672003

16

Maxwell PHWiesener MSChang GWClifford SCVaux ECCockman ME: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:2712751999

17

Mazumdar JDondeti VSimon MC: Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 13:431943282009

18

Mazur PKEinwächter HLee MSipos BNakhai HRad R: Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107:13438134432010

19

Moellering RECornejo MDavis TNDel Bianco CAster JCBlacklow SC: Direct inhibition of the NOTCH transcription factor complex. Nature 462:1821882009

20

Murphy PALam MTWu XKim TNVartanian SMBollen AW: Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci U S A 105:10901109062008

21

Noguera-Troise IDaly CPapadopoulos NJCoetzee SBoland PGale NW: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:103210372006

22

Ohishi KKatayama NShiku HVarnum-Finney BBernstein ID: Notch signalling in hematopoiesis. Semin Cell Dev Biol 14:1431502003

23

Ohtsuka TIshibashi MGradwohl GNakanishi SGuillemot FKageyama R: Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 18:219622071999

24

Pannuti AForeman KRizzo POsipo CGolde TOsborne B: Targeting Notch to target cancer stem cells. Clin Cancer Res 16:314131522010

25

Park DMZhuang ZChen LSzerlip NMaric ILi J: von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4:e602007

26

Phng LKGerhardt H: Angiogenesis: a team effort coordinated by notch. Dev Cell 16:1962082009

27

Rae FKStephenson SANicol DLClements JA: Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88:7267322000

28

Ramírez-Bergeron DLRunge ADahl KDFehling HJKeller GSimon MC: Hypoxia affects mesoderm and enhances hemangioblast specification during early development. Development 131:462346342004

29

Renshaw SImmunochemical staining techniques. Renshaw S: Immunohistochemistry OxfordshireScion2007. 4579

30

Roberts AMOhh M: Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20:83892008

31

Sainson RCHarris AL: Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 11:41512008

32

Sang LRoberts JMColler HA: Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 16:17262010

33

Shih IeMWang TL: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67:187918822007

34

Sjölund JJohansson MManna SNorin CPietras ABeckman S: Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118:2172282008

35

Solecki DJLiu XLTomoda TFang YHatten ME: Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 31:5575682001

36

Varnum-Finney BPurton LEYu MBrashem-Stein CFlowers DStaats S: The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood 91:408440911998

37

Vortmeyer AOFrank SJeong SYYuan KIkejiri BLee YS: Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 63:705170552003

38

Westfall SDSachdev SDas PHearne LBHannink MRoberts RM: Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. Stem Cells Dev 17:8698812008

39

Wu YCain-Hom CChoy LHagenbeek TJde Leon GPChen Y: Therapeutic antibody targeting of individual Notch receptors. Nature 464:105210572010

40

Xu PYu SJiang RKang CWang GJiang H: Differential expression of Notch family members in astrocytomas and medulloblastomas. Pathol Oncol Res 15:7037102009

41

Yin LVelazquez OCLiu ZJ: Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80:6907012010

42

Zeuner AFrancescangeli FSignore MVenneri MAPedini FFelli N: The Notch2-Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. Cell Death Differ 18:3713802011

43

ZhuGe QZhong MZheng WYang GYMao XXie L: Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain 132:323132412009

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 30 30 16
Full Text Views 58 58 11
PDF Downloads 51 51 4
EPUB Downloads 0 0 0

PubMed

Google Scholar